logo
Public Advisory - Two lots of Seasonale birth control recalled due to extra placebo pills

Public Advisory - Two lots of Seasonale birth control recalled due to extra placebo pills

Yahoo2 days ago

OTTAWA, ON, June 4, 2025 /CNW/ -
Summary
Product: Seasonale (0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol) (DIN 02296659)
Issue: Health products – Product quality
What to do: Do not skip doses or stop taking Seasonale. If your package contains placebo (white) pills in tray 1 or 2 of the blister cards, do not take them and return the product to your pharmacy for a replacement or alternative product. If you cannot get to a pharmacy right away, take the next active (pink) pill in the proper order as noted in the instructions until you are able to contact your pharmacist and obtain a replacement or alternative product.
Affected products
Product
DIN
Lot
Expiry
Seasonale (0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol)
02296659
100059661
100069150
31-Jan-2026
30-Sep-2026
IssueTeva Canada Ltd. is recalling two lots of Seasonale prescription birth control after receiving a complaint that a package contained an extra row of placebo (white) pills where there should be none. Taking placebo pills instead of active (pink) pills may reduce the effectiveness of the product and could lead to an unintended pregnancy.
As shown in Photo 1, Seasonale pills come packaged in a dispenser containing a 13-week (91-day) supply divided into three blister cards, each placed on its own tray:
Trays 1 and 2 each hold a blister card with 28 active (pink) pills.
Tray 3 holds a blister card with 35 pills: 28 active (pink) pills and 7 placebo (white) pills.
Photo 2 shows three blister cards as well, but the tray 2 (middle blister card) contains an extra row of placebo (white) pills where there should be none.
Seasonale should be taken daily unless otherwise directed by your prescriber to prevent pregnancy. Taking the pills in the proper order, according to the instructions that accompany the product, is important for preventing pregnancy. Taking a placebo (white) pill out of order could lead to unplanned pregnancy and other side effects, including spotting and irregular bleeding.
Health Canada is monitoring the company's recall and investigation, including its implementation of corrective and preventive actions to prevent this issue from reoccurring. The Department will inform the public if any new health risks are identified.
What you should do
Do not stop taking Seasonale. Do not skip taking any active (pink) pills until the very last row of tray 3 (which is the placebo [white] pills).
Check your package. If it contains placebo (white) pills in tray 1 or 2 of the blister cards, do not take them, and return the product to your pharmacy for a replacement or alternative product.
If you cannot get to a pharmacy right away, take the next active (pink) pill in the proper order as noted in the instructions until you are able to contact your pharmacist and obtain a replacement or alternative product.
If you are unsure whether your package contains the correct pills, talk to your pharmacist.
If you took a placebo (white) pill instead of an active (pink) pill from trays 1 or 2, or if you are unsure, you should also use another method of non-hormonal back-up contraception (such as condoms) and consult with your health care professional.
Talk to a health care professional if you have any other questions or concerns about your birth control product.
Contact Teva Canada Ltd. by calling toll-free at 1-800-268-4127, Option 3, or by email at druginfo@tevacanada.com if you have questions about this recall.
Report any health product-related side effects or complaints to Health Canada.
Également disponible en français
SOURCE Health Canada (HC)
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2025/04/c1025.html

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Canada Glucose Monitoring Device Market Forecast & Opportunities, 2025-2030: Increasing Adoption of Advanced Glucose Monitoring Technologies
Canada Glucose Monitoring Device Market Forecast & Opportunities, 2025-2030: Increasing Adoption of Advanced Glucose Monitoring Technologies

Yahoo

time33 minutes ago

  • Yahoo

Canada Glucose Monitoring Device Market Forecast & Opportunities, 2025-2030: Increasing Adoption of Advanced Glucose Monitoring Technologies

The Canada glucose monitoring device market is expanding due to rising diabetes cases and technological advancements. Key opportunities include increased demand for continuous and flash glucose monitors for proactive management. However, high costs limit access, especially for uninsured patients. Advanced CGMs and data-integrated solutions offer growth potential. Canadian Glucose Monitoring Device Market Dublin, June 06, 2025 (GLOBE NEWSWIRE) -- The "Canada Glucose Monitoring Device Market, By Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to offering. The Canada Glucose Monitoring Device Market was valued at USD 1.23 Billion in 2024 and is expected to reach USD 2.54 Billion by 2030, rising at a CAGR of 12.85% The market is witnessing significant expansion driven by rapid technological advancements and the rising prevalence of diabetes across the country. With diabetes recognized as a pressing public health concern, demand for efficient glucose monitoring tools has surged. According to Health Canada, the global diabetic population is expected to more than double by 2050, underscoring the urgent need for accessible monitoring solutions. As a major contributor to global morbidity and mortality, diabetes has propelled the adoption of devices like continuous and flash glucose monitors, which offer real-time data and enable proactive disease management. Rising Prevalence of Diabetes in Canada The growing number of diabetes cases across Canada is a critical factor driving the glucose monitoring device market. By 2020-2021, approximately 3.7 million Canadians, or 9.4% of the population aged one and above, were diagnosed with diabetes, a figure that climbs to 27% among those aged 65 and older. This demographic shift underscores the escalating need for effective blood sugar monitoring tools. Devices such as continuous glucose monitors (CGMs) and flash glucose monitors (FGMs) have become essential for real-time tracking and management of glucose levels. They support timely interventions and help mitigate complications like cardiovascular disease, kidney damage, and neuropathy, thereby improving patient outcomes and quality of life. High Cost of Advanced Monitoring Devices The cost of advanced glucose monitoring technologies remains a major hurdle to widespread use. While some government programs offer financial assistance, not all individuals qualify, and personal expenses can be steep. For instance, individuals with type 1 diabetes in Alberta may face up to $7,000 in annual out-of-pocket expenses, while those with type 2 diabetes could spend as much as $6,000. These costs include the initial device, sensors, and transmitters, which can be financially burdensome for patients lacking sufficient insurance coverage. This financial barrier often restricts access to newer technologies, affecting diabetes care and control among economically vulnerable populations. Adoption of Advanced Glucose Monitoring Technologies A prominent trend in the Canadian market is the increasing shift towards advanced glucose monitoring systems, particularly CGMs. These devices deliver continuous glucose readings, offering superior glycemic management and reducing complications such as hypo- and hyperglycemia. Compared to traditional finger-prick methods, CGMs enhance user convenience and improve quality of life. Integration with insulin pumps and mobile apps has enabled real-time data sharing and automated insulin delivery, allowing healthcare providers to personalize treatment plans more effectively. As awareness of these benefits grows, the uptake of advanced glucose monitoring technologies is expected to rise steadily across Canada. Key Attributes: Report Attribute Details No. of Pages 70 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $1.23 Billion Forecasted Market Value (USD) by 2030 $2.54 Billion Compound Annual Growth Rate 12.8% Regions Covered Canada Report Scope Key Market Players: Medtronic of Canada Ltd Abbott Canada. Johnson & Johnson Inc/Canada Braun of Canada F. Hoffmann-La Roche Limited. Ascensia Diabetes Care. Sanofi-Aventis Canada Inc. Eli Lilly Canada Inc. Canada Glucose Monitoring Device Market, By Product Type: Self-Blood Glucose Monitoring Devices Continuous Glucose Monitoring Devices Canada Glucose Monitoring Device Market, By Application: Type 1 Diabetes Type 2 Diabetes Gestational Diabetes Canada Glucose Monitoring Device Market, By End User: Home Care Settings Hospital Others Canada Glucose Monitoring Device Market, By Region: Ontario Quebec Alberta British Columbia Saskatchewan and Manitoba Rest of Canada For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Canadian Glucose Monitoring Device Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

ZEISS CLARUS 700 Receives NMPA Approval in China
ZEISS CLARUS 700 Receives NMPA Approval in China

Yahoo

time13 hours ago

  • Yahoo

ZEISS CLARUS 700 Receives NMPA Approval in China

ZEISS Medical Technology expands retinal insights for ophthalmologists with ultra-widefield, high-resolution imaging capabilities JENA, Germany and SHANGHAI, June 5, 2025 /CNW/ -- ZEISS Medical Technology announced today that the CLARUS® 700 from ZEISS has received National Medical Products Administration (NMPA) approval in China, offering advanced retinal diagnostic capabilities with ultra-widefield, high-resolution images in True Color and unsurpassed quality. The fundus imaging device with Fluorescein Angiography helps eye care specialists in China unlock the full potential of their clinic's retina workflow to support improved patient vision preservation. "ZEISS CLARUS 700 represents a major step forward in retinal imaging," emphasizes Anuj Kalra, Head of Chronic Disease Management at ZEISS Medical Technology. "By seamlessly integrating ultra-widefield Fluorescein Angiography (FA) imaging with true-color reproduction, this system delivers unprecedented clarity for comprehensive visualization from the macular region to the extreme retinal periphery, enhancing efficiency and supporting precise decision-making within the ZEISS Retina Workflow." "Integrating ultra-widefield imaging, unsurpassed clarity, and AI-enhanced capture, the CLARUS 700 redefines fundus angiography benchmarks. It will provide unparalleled diagnostic precision for Chinese doctors and unprecedented comfort for their patients," says Maxwell Liu, Head of Sales & Services at ZEISS Medical Technology China. Ultra-widefield fluorescein angiography serves as a highly valuable examination tool for assessing nonperfused retinal areas. The ZEISS CLARUS 700 HD ultra-widefield fundus imaging camera is an advanced retinal imaging system that provides True Color, high-resolution images. It captures 133°1 in a single image and up to 267° with multiple captures, offering detailed views of the retina. Equipped with both fluorescein angiography and live infrared imaging capabilities, the CLARUS 700 aids in diagnosing and monitoring retinal diseases2. Furthermore, the fundus imaging camera offers innovative technology features including PrecisionFocus for quickly seeing details in the regions of interest, QuickCompare to compare pathology changes observed in past patient visits, and AutoBright so ophthalmologists can spend more time analyzing images and less time adjusting them. More information about the CLARUS® 700 from ZEISS can be found here. 1 CLARUS 700#white-paper2 Xiao, Y., Dan, H., Du, X. et al. Assessment of early diabetic retinopathy severity using ultra-widefield Clarus versus conventional five-field and ultra-widefield Optos fundus imaging. Sci Rep 13, 17131 (2023). Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals' content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support. Contact for investorsSebastian FrericksDirector Investor RelationsCarl Zeiss Meditec AGPhone: +49 3641 220 116Mail: Contact for the pressFrank SmithHead of Global Communications OphthalmologyCarl Zeiss Meditec +49 3641 220 331Mail: Brief Profile Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. For further information visit: View original content to download multimedia: SOURCE Carl Zeiss Meditec AG View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

ZEISS CLARUS 700 Receives NMPA Approval in China
ZEISS CLARUS 700 Receives NMPA Approval in China

Yahoo

time14 hours ago

  • Yahoo

ZEISS CLARUS 700 Receives NMPA Approval in China

ZEISS Medical Technology expands retinal insights for ophthalmologists with ultra-widefield, high-resolution imaging capabilities JENA, Germany and SHANGHAI, June 5, 2025 /CNW/ -- ZEISS Medical Technology announced today that the CLARUS® 700 from ZEISS has received National Medical Products Administration (NMPA) approval in China, offering advanced retinal diagnostic capabilities with ultra-widefield, high-resolution images in True Color and unsurpassed quality. The fundus imaging device with Fluorescein Angiography helps eye care specialists in China unlock the full potential of their clinic's retina workflow to support improved patient vision preservation. "ZEISS CLARUS 700 represents a major step forward in retinal imaging," emphasizes Anuj Kalra, Head of Chronic Disease Management at ZEISS Medical Technology. "By seamlessly integrating ultra-widefield Fluorescein Angiography (FA) imaging with true-color reproduction, this system delivers unprecedented clarity for comprehensive visualization from the macular region to the extreme retinal periphery, enhancing efficiency and supporting precise decision-making within the ZEISS Retina Workflow." "Integrating ultra-widefield imaging, unsurpassed clarity, and AI-enhanced capture, the CLARUS 700 redefines fundus angiography benchmarks. It will provide unparalleled diagnostic precision for Chinese doctors and unprecedented comfort for their patients," says Maxwell Liu, Head of Sales & Services at ZEISS Medical Technology China. Ultra-widefield fluorescein angiography serves as a highly valuable examination tool for assessing nonperfused retinal areas. The ZEISS CLARUS 700 HD ultra-widefield fundus imaging camera is an advanced retinal imaging system that provides True Color, high-resolution images. It captures 133°1 in a single image and up to 267° with multiple captures, offering detailed views of the retina. Equipped with both fluorescein angiography and live infrared imaging capabilities, the CLARUS 700 aids in diagnosing and monitoring retinal diseases2. Furthermore, the fundus imaging camera offers innovative technology features including PrecisionFocus for quickly seeing details in the regions of interest, QuickCompare to compare pathology changes observed in past patient visits, and AutoBright so ophthalmologists can spend more time analyzing images and less time adjusting them. More information about the CLARUS® 700 from ZEISS can be found here. 1 CLARUS 700#white-paper2 Xiao, Y., Dan, H., Du, X. et al. Assessment of early diabetic retinopathy severity using ultra-widefield Clarus versus conventional five-field and ultra-widefield Optos fundus imaging. Sci Rep 13, 17131 (2023). Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals' content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support. Contact for investorsSebastian FrericksDirector Investor RelationsCarl Zeiss Meditec AGPhone: +49 3641 220 116Mail: Contact for the pressFrank SmithHead of Global Communications OphthalmologyCarl Zeiss Meditec +49 3641 220 331Mail: Brief Profile Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. For further information visit: View original content to download multimedia: SOURCE Carl Zeiss Meditec AG View original content to download multimedia:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store